原发性肝癌血管介入治疗研究现状概述

Summary of research status of vascular intervention for primary liver cancer

1978年Yamada教授开创性提出了经导管动脉化疗栓塞(TACE)的概念,标志着经血管介入治疗进入了一个新的阶段。得益于近年来介入器材的革新与诊疗观念的进步,在传统介入治疗的基础上又涌现了载药微球TACE(DEB-TACE)、经动脉放射栓塞(TARE)等新型局部治疗方式。经血管介入治疗因其微创、疗效确切的特点,目前被全球各大指南推荐并应用于中晚期肝癌的诊疗。2018年起,随着靶向、免疫治疗时代的来临,经血管介入治疗联合靶向、免疫治疗的综合治疗模式获得了广泛的推崇和应用,相应的研究进展正加速改变肝癌的诊疗规范。

In 1978,Professor Yamada summarized his many years of experience in interventional therapy and pioneered the concept of transcatheter arterial chemoembolization(TACE),which marked a new stage of transvascular inter-ventional therapy.Thanks to the innovation of interventional devices and advances in treatment concepts in recent years,new local treatment modalities such as drug-eluting bead TACE(DEB-TACE)and transarterial radioembolization have emerged on the basis of traditional interventional therapy.Since 2018,with the advent of the era of targeted and immunotherapy,the comprehensive treatment model of transvascular interventional therapy combined with targeted and immunotherapy has gained widespread esteem and application,and the corresponding research advances are accelerating to change the treatment norms of liver cancer.